Anbio Biotechnology (NNNN) Common Equity (2023 - 2025)

Anbio Biotechnology (NNNN) has 3 years of Common Equity data on file, last reported at $30.2 million in Q4 2025.

• On a quarterly basis, Common Equity rose 75.41% year-over-year to $30.2 million in Q4 2025; TTM through Dec 2025 was $30.2 million, a 75.41% increase from a year earlier, with the FY2025 full-year figure at $30.2 million, up 75.41% from the prior year.
• Common Equity for Q4 2025 stood at $30.2 million, down from $27549.5 billion in the prior quarter.
• Over the last five years, Common Equity for NNNN reached as high as $27549.5 billion in Q2 2025 and fell as low as $14.8 million in Q4 2023.
• Historically, Common Equity has averaged $6887.4 billion across 3 years, with a median of $23.7 million in 2024.
• Across the five-year window, Common Equity gained 16.01% in 2024 and soared 75.41% in 2025, its largest moves.
• Year by year, Common Equity stood at $14.8 million in 2023, then climbed by 16.01% to $17.2 million in 2024, then surged by 75.41% to $30.2 million in 2025.
• Per Business Quant data, the three most recent Common Equity figures were $30.2 million in Q4 2025, $27549.5 billion in Q2 2025, and $17.2 million in Q4 2024.